Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of
Jay Overholser1, Linlin Guo1, Pravin T P Kaumaya2
1Department of Obstetrics & Gynecology, The Ohio State University Wexner Medical Center.
Abstract:
The inhibition of checkpoint receptors (PD-1, PD-L1, and CTLA-4) with monoclonal antibodies has shown great benefit in clinical trials for treating cancer patients and has become a mainstay approach in modern cancer immunotherapy. However, only a subset of patients respond to checkpoint monoclonal antibody immunotherapy. Therefore, it is urgent to develop new therapeutic strategies against cancer. A novel B-cell peptide epitope PDL1 (programmed death ligand 1) cancer vaccine has been developed, with amino acids 130-147 linked to the MVF peptide ("promiscuous" T-cell measles virus fusion protein) via a GPSL linker. Preclinical testing has indicated that this PDL1 vaccine (PDL1-Vaxx) effectively stimulates highly immunogenic antibodies in animals. Animals immunized with PDL1-Vaxx show reduced tumor burden and extended survival rates in various animal cancer models. The mechanisms of action indicate that vaccine-elicited antibodies inhibit tumor cell proliferation, induce apoptosis, and block the PD-1/PD-L1 interaction. This manuscript introduces a magnetic bead-based assay that uses a dual-reporter flow analysis system to evaluate the PD-1/PD-L1 interaction and its blockade by the anti-PDL1 antibodies raised against the PDL1-Vaxx.
Insights
A new cancer vaccine targeting programmed death ligand 1 (PDL1) elicits antibodies that reduce tumor growth and improve survival in preclinical models. This vaccine offers a promising new strategy for cancer immunotherapy beyond current checkpoint inhibitors.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Monoclonal antibodies targeting checkpoint receptors (PD-1, PD-L1, CTLA-4) are mainstays in cancer immunotherapy but benefit only a subset of patients.
- There is an urgent need for novel therapeutic strategies to overcome limitations of current cancer treatments.
Purpose of the Study:
- To introduce a novel B-cell peptide epitope vaccine targeting programmed death ligand 1 (PDL1).
- To evaluate the efficacy of the PDL1 vaccine (PDL1-Vaxx) in preclinical cancer models.
- To describe a magnetic bead-based assay for evaluating PD-1/PD-L1 interaction blockade.
Main Methods:
- Development of a PDL1 peptide epitope vaccine (amino acids 130-147) linked to the MVF peptide via a GPSL linker.
- Preclinical testing of PDL1-Vaxx in animal cancer models.
- Utilizing a magnetic bead-based assay with dual-reporter flow analysis to assess PD-1/PD-L1 interaction and blockade by anti-PDL1 antibodies.
Main Results:
- PDL1-Vaxx effectively stimulated highly immunogenic antibodies in animals.
- Immunization with PDL1-Vaxx led to reduced tumor burden and extended survival rates in various animal cancer models.
- Vaccine-elicited antibodies were shown to inhibit tumor cell proliferation, induce apoptosis, and block the PD-1/PD-L1 interaction.
Conclusions:
- The novel PDL1 cancer vaccine (PDL1-Vaxx) demonstrates significant preclinical efficacy in reducing tumor burden and improving survival.
- PDL1-Vaxx represents a promising new therapeutic strategy for cancer immunotherapy, potentially overcoming resistance to current checkpoint inhibitors.
- The developed assay provides a valuable tool for evaluating PD-1/PD-L1 blockade by anti-PDL1 antibodies.
